Mural Oncology granted stock options and restricted stock units to a new employee.

From GlobeNewswire: 2024-09-04 16:30:00

Mural Oncology plc granted non-statutory stock options and restricted stock units to a newly hired employee on September 3, 2024, under the Company’s 2024 Inducement Stock Option and Incentive Plan. The stock options have an exercise price of $3.16 per share and vest over four years, while the restricted stock units also vest over four years. The Company is focused on developing cytokine-based immunotherapies for cancer treatment, with their lead candidate, nemvaleukin, in potentially registrational trials for mucosal melanoma and platinum-resistant ovarian cancer. For more information, visit Mural Oncology’s website.



Read more at GlobeNewswire: Mural Oncology Reports Inducement Grants Under Nasdaq